FDA Grants Orphan Drug Status to Pasithea's ALS Drug PAS-004
KTTA has more than doubled off its 52-week low of $0.281.
Summary
The FDA has granted Orphan Drug Designation (ODD) to Pasithea Therapeutics' drug candidate, PAS-004, for the treatment of Amyotrophic Lateral Sclerosis (ALS). This is a significant regulatory milestone for the clinical-stage biotech, offering benefits such as tax credits, fee exemptions, and potential seven years of market exclusivity upon approval. This follows previous Fast Track and Rare Pediatric Disease Designations for PAS-004, highlighting consistent progress in its development. The company recently reported an improved Q1 net loss and a robust cash balance, providing a solid runway for its R&D efforts.
At the time of this announcement, KTTA was trading at $0.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.9M. The 52-week trading range was $0.28 to $2.06. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.